ALS biotech QurAlis gets $88M boost from 4 pharmas for pair of PhI studies

QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA approval of Amylyx Pharmaceuticals’ ALS therapy.

Kevin Eggan

Four biopharmas — Eli Lilly, Amgen, Sanofi and Mitsubishi Tanabe’s VC arm — are bankrolling a Series B...

Click to view original post